---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-095934"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2026-08-13T20:15:24+00:00"
generated_at: "2026-08-13T20:17:49.338752+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elutia secures up to $26M funding, reports Q2 net loss $7.6M; NXT-41x on track

## Summary
- Secured up to $26M: $15M Avenue Capital credit facility and up to $11M from SimpliDerm divestiture; no equity offering.
- Q2 net sales $2.4M (down from $2.7M); net loss $7.6M vs $9.6M; adjusted EBITDA loss $4.6M vs $3.0M.
- Surgeon survey: 86% say current matrices increase infection risk; 96% interested in NXT-41x; 92% would champion at hospital.
- NXT-41 FDA clearance expected 4Q 2026; NXT-41x 1H 2027; commercial launch 2028.
- Cash $19.9M; expects up to $34M additional from signed transactions including $8M BioEnvelope escrow.

## SEC filing metadata
- accession: 0001104659-26-095934
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2026-08-13T20:15:24+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465926095934/0001104659-26-095934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465926095934/elut-20260813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-095934
- JSON: https://secwatch.observer/filing/0001104659-26-095934.json
- Plain text: https://secwatch.observer/filing/0001104659-26-095934.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.